Morgan Stanley upgraded Sarepta Therapeutics Inc. (Nasdaq: SRPT) from and Equal Weight rating to an Overweight rating and lifted its price target from $33.00 to $60.00. Shares of the biopharmaceutical leaped $4.19 to close at $49.55.
Sarepta Therapeutics upgraded
October 02, 2017 at 19:40 PM EDT
